PAR1 Molekülinformation
Molecule Name
Protease-activated receptor-1
Molekülalias
F2R,coagulation factor II thrombin receptor,CF2R, HTR, PAR-1, PAR1, TR
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
Coagulation Factor II (Thrombin) Receptor，Proteinase-Activated Receptor 1，Coagulation Factor II Receptor，Protease-Activated Receptor 1，Protease Activated Receptor 1，Thrombin Receptor，HTR，Receptor， PAR-1，PAR1，F2R，Coagulation Factor II Thrombin Receptor，PAR-1，CF2R，TR
Molekülhintergrund
Coagulation factor II receptor is a 7-transmembrane receptor involved in the regulation of thrombotic response. Proteolytic cleavage leads to the activation of the receptor. F2R is a G-protein coupled receptor family member. Alternative splicing results in multiple transcript variants.
PAR1 Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Rusalatide | TRAP-508; TP-508 | Phase 1 Clinical | Baylor College Of Medicine, University Of Texas Medical Branch | Radius Fractures; Respiratory Distress Syndrome, Adult | Details |
| Andropaxar-39 | Andropaxar 39; Andropaxar-39 | Phase 1 Clinical | Shandong Qidu Pharmaceutical Co Ltd, Shandong University | Cardiovascular Diseases | Details |
| GP-2102 | GP-2102; GP2102 | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Dermatitis, Atopic | Details |